The Experts below are selected from a list of 222 Experts worldwide ranked by ideXlab platform

Yarbrough Dr - One of the best experts on this subject based on the ideXlab platform.

  • Ofloxacin versus Cephalexin in the treatment of skin, skin structure, and soft-tissue infections in adults.
    Clinical Therapeutics, 1991
    Co-Authors: Powers Rd, Snow Rm, Richard H Schwartz, Yarbrough Dr
    Abstract:

    A multicenter study was conducted to compare the safety and efficacy of oral ofloxacin with that of Cephalexin in microbiologic eradication of skin and skin-structure pathogens and the clinical treatment of skin and skin-structure infections. The subjects, 335 adult patients with acute localized infections of the skin, skin structure, or soft tissue, were randomly assigned to receive 400 mg of ofloxacin orally every 12 hours or 500 mg of Cephalexin orally every six hours for 10 days. At admission, 398 aerobic pathogens were isolated, the most common being Staphylococcus aureus (160 isolates), Streptococcus pyogenes (49), coagulase-negative staphylococci (30), Staphylococcus epidermidis (25), and Pseudomonas aeruginosa (10). Of 317 isolates tested against ofloxacin, 96% were susceptible, and of 325 tested against Cephalexin, 85% were susceptible (P less than 0.001). Microbiologic and clinical outcome were evaluated in 73 ofloxacin-treated patients and in 65 Cephalexin-treated patients. The causative pathogens were eradicated in 95% of the ofloxacin group and in 92% of the Cephalexin group. In the ofloxacin group, 75% were clinically cured and 23% improved, and in the Cephalexin group, 74% and 23%, respectively. Drug-related adverse experiences were reported by 14% of the 161 ofloxacin-treated patients and by 11% of the 162 Cephalexin-treated patients; gastrointestinal disturbances were reported by 8% and 7% and nervous system effects by 6% and 1%, respectively (P less than 0.05). It is concluded that both ofloxacin and Cephalexin are safe and effective in the treatment of skin and soft-tissue infections.

Fred Arthur Zar - One of the best experts on this subject based on the ideXlab platform.

Powers Rd - One of the best experts on this subject based on the ideXlab platform.

  • Ofloxacin versus Cephalexin in the treatment of skin, skin structure, and soft-tissue infections in adults.
    Clinical Therapeutics, 1991
    Co-Authors: Powers Rd, Snow Rm, Richard H Schwartz, Yarbrough Dr
    Abstract:

    A multicenter study was conducted to compare the safety and efficacy of oral ofloxacin with that of Cephalexin in microbiologic eradication of skin and skin-structure pathogens and the clinical treatment of skin and skin-structure infections. The subjects, 335 adult patients with acute localized infections of the skin, skin structure, or soft tissue, were randomly assigned to receive 400 mg of ofloxacin orally every 12 hours or 500 mg of Cephalexin orally every six hours for 10 days. At admission, 398 aerobic pathogens were isolated, the most common being Staphylococcus aureus (160 isolates), Streptococcus pyogenes (49), coagulase-negative staphylococci (30), Staphylococcus epidermidis (25), and Pseudomonas aeruginosa (10). Of 317 isolates tested against ofloxacin, 96% were susceptible, and of 325 tested against Cephalexin, 85% were susceptible (P less than 0.001). Microbiologic and clinical outcome were evaluated in 73 ofloxacin-treated patients and in 65 Cephalexin-treated patients. The causative pathogens were eradicated in 95% of the ofloxacin group and in 92% of the Cephalexin group. In the ofloxacin group, 75% were clinically cured and 23% improved, and in the Cephalexin group, 74% and 23%, respectively. Drug-related adverse experiences were reported by 14% of the 161 ofloxacin-treated patients and by 11% of the 162 Cephalexin-treated patients; gastrointestinal disturbances were reported by 8% and 7% and nervous system effects by 6% and 1%, respectively (P less than 0.05). It is concluded that both ofloxacin and Cephalexin are safe and effective in the treatment of skin and soft-tissue infections.

Christopher J Graber - One of the best experts on this subject based on the ideXlab platform.

  • a critical review of Cephalexin and cefadroxil for the treatment of acute uncomplicated lower urinary tract infection in the era of bad bugs few drugs
    International Journal of Antimicrobial Agents, 2020
    Co-Authors: Hien M Nguyen, Christopher J Graber
    Abstract:

    Abstract First-generation oral cephalosporins (Cephalexin and cefadroxil) have traditionally been considered second-line treatment options for uncomplicated lower urinary tract infections (uLUTIs).  However, in the current age of “bad bugs, few drugs”, where there are increasingly limited oral options against resistant Enterobacteriaceae, there is an urgent need to rethink how best to utilize the available antibiotic armamentarium.  This review examines the historical clinical trials and experimental studies of Cephalexin and cefadroxil, particularly through the modern lens of pharmacokinetics/pharmacodynamics (PK/PD), to better appreciate the efficacy of these drugs in uLUTIs.  Furthermore, newer cefazolin-Cephalexin surrogate testing, as recommended by the Clinical and Laboratory Standards Institute (CLSI) and the United States Committee on Antimicrobial Susceptibility Testing (USCAST), has recategorized Cephalexin in many instances from resistant to susceptible.  We conclude that Cephalexin and cefadroxil have very good early bacteriological and clinical cures in uLUTIs due to non-extended-spectrum beta-lactamase-producing (ESBL) Enterobacteriaceae comparable to many traditionally first-line agents.  Cephalexin can be conveniently administered as 500 mg twice or thrice daily, similar to cefadroxil (500 mg twice daily); therefore, either agent may be used as a fluoroquinolone-sparing alternative. Cephalexin may be the more practical choice for many clinicians because reliable antimicrobial susceptibility test interpretative criteria (STIC) are provided by CLSI, USCAST, and the European Committee on Antimicrobial Susceptibility Testing (EUCAST), whereas direct cefadroxil STIC is offered only by EUCAST.

Snow Rm - One of the best experts on this subject based on the ideXlab platform.

  • Ofloxacin versus Cephalexin in the treatment of skin, skin structure, and soft-tissue infections in adults.
    Clinical Therapeutics, 1991
    Co-Authors: Powers Rd, Snow Rm, Richard H Schwartz, Yarbrough Dr
    Abstract:

    A multicenter study was conducted to compare the safety and efficacy of oral ofloxacin with that of Cephalexin in microbiologic eradication of skin and skin-structure pathogens and the clinical treatment of skin and skin-structure infections. The subjects, 335 adult patients with acute localized infections of the skin, skin structure, or soft tissue, were randomly assigned to receive 400 mg of ofloxacin orally every 12 hours or 500 mg of Cephalexin orally every six hours for 10 days. At admission, 398 aerobic pathogens were isolated, the most common being Staphylococcus aureus (160 isolates), Streptococcus pyogenes (49), coagulase-negative staphylococci (30), Staphylococcus epidermidis (25), and Pseudomonas aeruginosa (10). Of 317 isolates tested against ofloxacin, 96% were susceptible, and of 325 tested against Cephalexin, 85% were susceptible (P less than 0.001). Microbiologic and clinical outcome were evaluated in 73 ofloxacin-treated patients and in 65 Cephalexin-treated patients. The causative pathogens were eradicated in 95% of the ofloxacin group and in 92% of the Cephalexin group. In the ofloxacin group, 75% were clinically cured and 23% improved, and in the Cephalexin group, 74% and 23%, respectively. Drug-related adverse experiences were reported by 14% of the 161 ofloxacin-treated patients and by 11% of the 162 Cephalexin-treated patients; gastrointestinal disturbances were reported by 8% and 7% and nervous system effects by 6% and 1%, respectively (P less than 0.05). It is concluded that both ofloxacin and Cephalexin are safe and effective in the treatment of skin and soft-tissue infections.